nnc0480-0389
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 5, 2020 (NCT04259801)
Timeline
Indications
Mechanism of action
GIPR agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05498610 | Phase 1 | Aug 11, 2022 | Novo Nordisk |
| NCT05153564 | Phase 1 | Dec 10, 2021 | Novo Nordisk |
| NCT05144984 | Phase 2 | Nov 29, 2021 | Novo Nordisk |
| NCT05046873 | Phase 1 | Sep 6, 2021 | Novo Nordisk |
| NCT05015894 | Phase 1 | Aug 30, 2021 | Novo Nordisk |
| NCT04878406 | Phase 1 | May 18, 2021 | Novo Nordisk |
| NCT04259801 | Phase 1 | Feb 5, 2020 | Novo Nordisk |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 7 | 7 | 2 | 2020 |
1 organizations
Page 1 / 1